The Korean government has emphasized the need to enact subordinate statutes to give preferential treatment to new drugs manufactured by Korea Innovative Pharmaceutical Companies and promises to prepare policy support.

This announcement reflects the authorities’ determination to find a way to provide preferential treatment for drug prices based on the “Research service for the preparation of subordinate statutes for preferential pricing of drugs developed by Korea Innovative Pharmaceutical Companies that correspond to the international trade order.”

However, the government had also expressed practical difficulties in its implementation, as providing pricing support for specific pharmac